Indications
Selexipag tablet is used to treat pulmonary arterial hypertension (PAH, WHO Group I). It helps delay the progression of the disease and lowers the risk of being admitted to hospital because of PAH.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Selexipag is a selective, non-prostanoid agonist of the IP prostacyclin receptor, and it is taken by mouth. It is a pale yellow crystalline powder that is practically insoluble in water. In solid form it is very stable, it doesn't absorb moisture and it isn't sensitive to light. Structurally, selexipag is quite different from prostacyclin itself.
In the body, carboxylesterase 1 hydrolyzes selexipag to its active metabolite, which is approximately 37-fold as potent as selexipag. Both selexipag and this metabolite are selective for the IP receptor over the other prostanoid receptors (EP1-4, DP, FP, and TP).
Pregnancy & Breastfeeding
There are no adequate and well controlled studies of Selexipag in pregnant women. It is not known if Selexipag passes into human milk. For a nursing mother, either Selexipag or breastfeeding should be stopped.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.